pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›earnings
earnings
save

TEVA PHARMACEUTICAL INDUSTRIES LTD earnings

July 29, 2026$TEVAupdated 2mo ago
community read0 votes

Anticipated earnings call for TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA).

view source ↗
Data sources
yahoo earnings
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

related news · 8

  • fiercebiotechSlate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials↗
  • fiercebiotechLilly pens $370M deal with OmniAb for ion channel collab, but details remain vague↗
  • fiercebiotechZealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision↗
  • endpointsJudge signs off on Teva's $35M settlement over delayed inhaler generics↗
  • biopharma diveAttovia adds to biotech IPO momentum with $289M offering↗
  • fiercebiotechMerck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials↗
  • fiercebiotechChutes & Ladders—Legend CEO departs without successor in place↗
  • endpointsGerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity↗

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?